

# Mar Riveiro-Barciela

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2064230/publications.pdf>

Version: 2024-02-01

71  
papers

2,888  
citations

393982

19  
h-index

189595

50  
g-index

75  
all docs

75  
docs citations

75  
times ranked

7200  
citing authors

#	ARTICLE	IF	CITATIONS
1	Retreatment With Immune Checkpoint Inhibitors After a Severe Immune-Related Hepatitis: Results From a Prospective Multicenter Study. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 732-740.	2.4	19
2	How to interpret viral markers in the management of chronic hepatitis B infection. <i>Clinical Microbiology and Infection</i> , 2022, 28, 355-361.	2.8	1
3	Effect of Hepatitis E Virus RNA Universal Blood Donor Screening, Catalonia, Spain, 2017-2020. <i>Emerging Infectious Diseases</i> , 2022, 28, 157-165.	2.0	9
4	Noninvasive Prediction of Outcomes in Autoimmune Hepatitis-Related Cirrhosis. <i>Hepatology Communications</i> , 2022, 6, 1392-1402.	2.0	5
5	Inspecting the Ribozyme Region of Hepatitis Delta Virus Genotype 1: Conservation and Variability. <i>Viruses</i> , 2022, 14, 215.	1.5	4
6	Standardized Hepatitis B Virus RNA Quantification in Untreated and Treated Chronic Patients: a Promising Marker of Infection Follow-Up. <i>Microbiology Spectrum</i> , 2022, 10, e0214921.	1.2	2
7	Early predictors of corticosteroid response in acute severe autoimmune hepatitis: a nationwide multicenter study. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, 131-143.	1.9	9
8	ACE Score Identifies HBeAg-negative Inactive Carriers at a Single-point Evaluation, Regardless of HBV Genotype. <i>Journal of Clinical and Translational Hepatology</i> , 2022, 000, 000-000.	0.7	1
9	Cost-effectiveness analysis of an active search to retrieve <sc>HCV</sc> patients lost to follow-up (<sc>RELINK</sc> strategy) and the impact of <sc>COVID</sc>-19. <i>Journal of Viral Hepatitis</i> , 2022, 29, 579-583.	1.0	7
10	Detailed stratified GWAS analysis for severe COVID-19 in four European populations. <i>Human Molecular Genetics</i> , 2022, 31, 3945-3966.	1.4	46
11	Hepatitis B Core-Related Antigen to Indicate High Viral Load: Systematic Review and Meta-Analysis of 10,397 Individual Participants. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 46-60.e8.	2.4	27
12	Etiologies and Features of Acute Viral Hepatitis in Spain. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1030-1037.	2.4	12
13	Reflex viral load testing in dried blood spots generated by plasma separation card allows the screening and diagnosis of chronic viral hepatitis. <i>Journal of Virological Methods</i> , 2021, 289, 114039.	1.0	17
14	The role of liver steatosis as measured with transient elastography and transaminases on hard clinical outcomes in patients with COVID-19. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482110165.	1.4	7
15	Sophisticated viral quasispecies with a genotype-related pattern of mutations in the hepatitis B X gene of HBeAg-ve chronically infected patients. <i>Scientific Reports</i> , 2021, 11, 4215.	1.6	3
16	Cancer immunotherapy in special challenging populations: recommendations of the Advisory Committee of Spanish Melanoma Group (GEM). , 2021, 9, e001664.		11
17	Hepatic sinusoidal obstruction syndrome associated with nivolumab: an uncommon adverse event related to immune checkpoint inhibitors. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2021, 30, 171-172.	0.5	11
18	Differential characteristics and outcomes of Asian and non-Asian patients with HBV-related hepatocellular carcinoma. <i>Liver International</i> , 2021, 41, 1922-1932.	1.9	15

#	ARTICLE	IF	CITATIONS
19	Acquired hepatocerebral degeneration in a metastatic neuroendocrine tumor long-term survivor – an update on neuroendocrine neoplasms' treatment: A case report. <i>World Journal of Hepatology</i> , 2021, 13, 611-619.	0.8	0
20	Incidences and Determinants of Functional Cure During Entecavir or Tenofovir Disoproxil Fumarate for Chronic Hepatitis B. <i>Journal of Infectious Diseases</i> , 2021, 224, 1890-1899.	1.9	40
21	One-quarter of chronic hepatitis D patients reach HDV-RNA decline or undetectability during the natural course of the disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 462-469.	1.9	25
22	Chronic hepatitis D associated with worse patient-reported outcomes than chronic hepatitis B. <i>JHEP Reports</i> , 2021, 3, 100280.	2.6	8
23	Naïve hepatitis B e antigen-negative chronic hepatitis B patients are at risk of carotid atherosclerosis: A prospective study. <i>World Journal of Gastroenterology</i> , 2021, 27, 5112-5125.	1.4	5
24	Treatment of Chronic Hepatitis B Virus with Oral Anti-Viral Therapy. <i>Clinics in Liver Disease</i> , 2021, 25, 725-740.	1.0	5
25	Barriers to linkage to care in hepatitis C patients with substance use disorders and dual diagnoses, despite centralized management. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482110165.	1.4	0
26	Assessing Liver Fibrosis Using the FIB4 Index in the Community Setting. <i>Diagnostics</i> , 2021, 11, 2236.	1.3	16
27	Long-term clinical outcomes in patients with chronic hepatitis delta: the role of persistent viraemia. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 158-166.	1.9	49
28	Deep-sequencing reveals broad subtype-specific HCV resistance mutations associated with treatment failure. <i>Antiviral Research</i> , 2020, 174, 104694.	1.9	39
29	Role of Biomarkers in Guiding Cure of Viral Hepatitis B. <i>Seminars in Liver Disease</i> , 2020, 40, 049-060.	1.8	13
30	Outcome and risk of de novo Hepatitis B after liver transplantation: Are all anti-HBc-positive grafts the same?. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2020, 44, 791-793.	0.7	1
31	Application of EASL 2017 criteria for switching hepatitis B patients from tenofovir disoproxil to entecavir or tenofovir alafenamide. <i>Digestive and Liver Disease</i> , 2020, 52, 1164-1169.	0.4	7
32	Toxicities from immunotherapy: From clinical trials to real-world clinical practice. <i>Medicina Clínica (English Edition)</i> , 2020, 155, 541-547.	0.1	0
33	Genomewide Association Study of Severe Covid-19 with Respiratory Failure. <i>New England Journal of Medicine</i> , 2020, 383, 1522-1534.	13.9	1,548
34	An electronic alert system increases screening for hepatitis B and C and improves management of patients with haematological disorders. <i>Scientific Reports</i> , 2020, 10, 3038.	1.6	11
35	Optimal management of chronic hepatitis B patients receiving nucleos(t)ide analogues. <i>Liver International</i> , 2020, 40, 15-21.	1.9	13
36	Editorial: rapid disease progression in hepatitis delta – can we turn the tide? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 174-175.	1.9	1

#	ARTICLE	IF	CITATIONS
37	Unexpected long-lasting anti-HEV IgM positivity: Is HEV antigen a better serological marker for hepatitis E infection diagnosis?. <i>Journal of Viral Hepatitis</i> , 2020, 27, 747-753.	1.0	26
38	Immune-related hepatitis related to checkpoint inhibitors: Clinical and prognostic factors. <i>Liver International</i> , 2020, 40, 1906-1916.	1.9	43
39	Toxicities from immunotherapy: From clinical trials to real-world clinical practice. <i>Medicina Clínica</i> , 2020, 155, 541-547.	0.3	8
40	Simple predictive models identify patients with COVID-19 pneumonia and poor prognosis. <i>PLoS ONE</i> , 2020, 15, e0244627.	1.1	9
41	Conservation and variability of hepatitis B core at different chronic hepatitis stages. <i>World Journal of Gastroenterology</i> , 2020, 26, 2584-2598.	1.4	8
42	Simple predictive models identify patients with COVID-19 pneumonia and poor prognosis. , 2020, 15, e0244627.		0
43	Simple predictive models identify patients with COVID-19 pneumonia and poor prognosis. , 2020, 15, e0244627.		0
44	Simple predictive models identify patients with COVID-19 pneumonia and poor prognosis. , 2020, 15, e0244627.		0
45	Simple predictive models identify patients with COVID-19 pneumonia and poor prognosis. , 2020, 15, e0244627.		0
46	Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs. <i>Journal of Hepatology</i> , 2019, 71, 666-672.	1.8	67
47	Sclerosing Cholangitis Related to IgG4: Not Always a Curable Entity. <i>Annals of Hepatology</i> , 2019, 18, 215-219.	0.6	4
48	Decompensated Liver Disease due to Primary Hepatic Amyloidosis: Is Liver Transplantation Still Mandatory?. <i>Hepatology</i> , 2019, 69, 2701-2703.	3.6	2
49	Acute liver failure due to immune-mediated hepatitis successfully managed with plasma exchange: New settings call for new treatment strategies?. <i>Journal of Hepatology</i> , 2019, 70, 564-566.	1.8	45
50	Factors Associated With Rates of HBsAg Seroclearance in Adults With Chronic HBV Infection: A Systematic Review and Meta-analysis. <i>Gastroenterology</i> , 2019, 156, 635-646.e9.	0.6	162
51	Characterization of hepatitis B virus X gene quasispecies complexity in mono-infection and hepatitis delta virus superinfection. <i>World Journal of Gastroenterology</i> , 2019, 25, 1566-1579.	1.4	7
52	Long-term safety and efficacy of nucleo(t)side analogue therapy in hepatitis B. <i>Liver International</i> , 2018, 38, 84-89.	1.9	38
53	Quantitative characterization of hepatitis delta virus genome edition by next-generation sequencing. <i>Virus Research</i> , 2018, 243, 52-59.	1.1	11
54	Thrombotic thrombocytopenic purpura relapse induced by acute hepatitis E transmitted by cryosupernatant plasma and successfully controlled with ribavirin. <i>Transfusion</i> , 2018, 58, 2501-2505.	0.8	14

#	ARTICLE	IF	CITATIONS
55	Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and Cirrhosis. <i>Gastroenterology</i> , 2018, 155, 1120-1127.e4.	0.6	76
56	Gallstone ileus secondary to a cholecystocolonic fistula. <i>Gastroenterology y Hepatología</i> , 2018, 41, 510-511.	0.2	3
57	Derrame pleural izquierdo secundario a infartos espléncicos en una paciente con cirrosis hepática. <i>Medicina Clínica</i> , 2017, 148, 144-145.	0.3	0
58	Effectiveness and Safety of Entecavir or Tenofovir in a Spanish Cohort of Chronic Hepatitis B Patients: Validation of the Page-B Score to Predict Hepatocellular Carcinoma. <i>Digestive Diseases and Sciences</i> , 2017, 62, 784-793.	1.1	55
59	Left pleural effusion secondary to splenic infarctions in a patient with liver cirrhosis. <i>Medicina Clínica (English Edition)</i> , 2017, 148, 144-145.	0.1	0
60	Rapid liver and spleen stiffness improvement in compensated advanced chronic liver disease patients treated with oral antivirals. <i>Therapeutic Advances in Gastroenterology</i> , 2017, 10, 619-629.	1.4	45
61	Inferior Cava Vein Syndrome and Heart Compression Due to a Giant Liver Cyst. <i>American Journal of Gastroenterology</i> , 2017, 112, 984.	0.2	5
62	Red blood cell transfusion-transmitted acute hepatitis E in an immunocompetent subject in Europe: a case report. <i>Transfusion</i> , 2017, 57, 244-247.	0.8	41
63	Tenofovir Alafenamide Fumarate: A New Tenofovir Prodrug for the Treatment of Chronic Hepatitis B Infection. <i>Journal of Infectious Diseases</i> , 2017, 216, S792-S796.	1.9	21
64	Evidence of an Exponential Decay Pattern of the Hepatitis Delta Virus Evolution Rate and Fluctuations in Quasispecies Complexity in Long-Term Studies of Chronic Delta Infection. <i>PLoS ONE</i> , 2016, 11, e0158557.	1.1	19
65	Tenofovir discontinuation after long-term viral suppression in HBeAg negative chronic hepatitis B. Can HBsAg levels be useful?. <i>Journal of Clinical Virology</i> , 2015, 68, 61-68.	1.6	15
66	Phylogenetic Demonstration of Hepatitis E Infection Transmitted by Pork Meat Ingestion. <i>Journal of Clinical Gastroenterology</i> , 2015, 49, 165-168.	1.1	80
67	Management of direct-acting antiviral agent failures. <i>Journal of Hepatology</i> , 2015, 63, 1511-1522.	1.8	73
68	Hepatitis E virus: new faces of an old infection. <i>Annals of Hepatology</i> , 2013, 12, 861-70.	0.6	11
69	A 79-Year-Old Man With Dyspnea, Dysphagia, and Weakness. <i>Chest</i> , 2012, 142, 252-255.	0.4	7
70	Palmoplantar pustulosis and chest pain. <i>Lancet, The</i> , 2012, 379, e49.	6.3	1
71	The Low Incidence of Viral Hepatitis Reactivation Among Subjects on Immunotherapy Reduces the Impact of Suboptimal Screening Rate. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	3